• If you are wondering whether iRhythm Holdings at around US$135.90 is still a sensible entry point or more of a hold, a closer look at its valuation can help frame that decision.
• The stock has pulled back recently, with a 7 day return of an 11.7% decline and a 30 day return of a 15.9% decline, although the 1 year return sits at 24.2% and the 3 year return at 15.0%.
• These moves sit against a backdrop of ongoing interest in digital cardiac monitoring and iRhythm's role in that space, which continues to draw attention from investors focused on healthcare technology. Broader sector sentiment and shifting risk views around high growth healthcare names are likely feeding into the recent ups and downs in the share price.
• On our checks, iRhythm scores a valuation score of 3 out of 6. Next, we will look at how different valuation approaches assess the stock and then finish with a way to put those numbers into a fuller investing context.

iRhythm Holdings delivered 24.2% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry.

Approach 1: iRhythm Holdings Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of the cash a company may generate in the future and discounts those cash flows back to a single value today. The goal is to compare that estimate with the current share price to see how the market is pricing the business.

For iRhythm Holdings, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The company’s last twelve months free cash flow is about $31.6 million. Analyst estimates and subsequent extrapolations have free cash flow reaching $61.1 million in 2026 and $186.0 million in 2028, with further projected figures extending out to 2035, all discounted back to today in the model.

Based on these inputs, the DCF model produces an intrinsic value estimate of roughly $234.48 per share. Compared with the recent share price of about $135.90, the model output indicates the stock is approximately 42.0% below this intrinsic value estimate.

Result: MODEL SUGGESTS UNDERVALUATION

Our Discounted Cash Flow (DCF) analysis suggests iRhythm Holdings is undervalued by 42.0%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for iRhythm Holdings.

Approach 2: iRhythm Holdings Price vs Sales

For a company like iRhythm that is focused on scaling its cardiac monitoring platform, the P/S ratio is often a practical gauge because it compares what you are paying to the revenue the business is already generating, even if earnings are not yet the main focus.

In general, higher growth expectations and lower perceived risk can support a higher “normal” multiple, while slower growth and higher risk usually point to a lower multiple. That context matters when you compare simple P/S ratios across companies.

iRhythm currently trades on a P/S of 5.88x. This sits above the Medical Equipment industry average of 2.94x and also above the peer group average of 4.98x. Simply Wall St’s Fair Ratio for iRhythm is 4.31x. This Fair Ratio is a proprietary estimate of what a reasonable P/S might be given the company’s growth profile, profit margins, industry, market cap and specific risks. It is therefore more tailored than a basic comparison with peers or the broad industry.

Compared with that Fair Ratio of 4.31x, the current 5.88x P/S suggests the shares are trading at a premium to what this framework would consider reasonable.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 21 top founder-led companies.

Upgrade Your Decision Making: Choose your iRhythm Holdings Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple way for you to write the story behind your numbers by linking your view on iRhythm Holdings, such as whether you think revenue can reach about US$1.1b with profit margins near 4.0% and a future P/E around 199x, or whether you lean closer to the more cautious earnings and price targets. This can then be connected to a concrete forecast and Fair Value on Simply Wall St’s Community page. You can compare that Fair Value to the current price to help decide whether the stock looks attractive or stretched, while the platform keeps your Narrative updated automatically as new news, guidance and earnings on iRhythm come through.

Do you think there's more to the story for iRhythm Holdings? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.